The US Patent and Trademark Office (USPTO) has granted a Notice of Allowance for Tenax Therapeutics’ patent application covering its oral levosimendan, TNX-103, to treat pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF).
Once granted, the patent will offer intellectual property protection until December 2040 and additional protection to the company in the US.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
In March, the USPTO issued a patent for the intravenous administration of levosimendan for the same indication.
Levosimendan serves as a potassium ATP channel activator and a calcium sensitiser.
The latest patent for the drug is based on important findings obtained from the HELP Study.
Findings showed that PH-HFpEF patients treated with levosimendan had a statistically significant improvement in a six-minute walk distance of 29 metres, compared to a placebo.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataTenax Therapeutics chief medical officer Dr Stuart Rich said: “Based on its unique mechanistic properties as both a potassium ATP channel activator and calcium sensitiser, we believe oral levosimendan has a unique opportunity to become the first therapy ever approved for the treatment of PH-HFpEF, the most common type of PH globally.
“As demonstrated in the Phase II HELP Study, intravenous levosimendan is the only drug to have shown a significant improvement in exercise capacity for this patient population.
“Importantly, we have also received guidance from the FDA that the same six-minute walking test used in the Phase II HELP Study can serve as the primary endpoint in our Phase III programme.”
Furthermore, the company plans to commence a Phase III trial of the levosimendan oral formulation this year.
